A new once-daily dual bronchodilator is now available across England for the treatment of chronic obstructive pulmonary disease, its manufacturers have announced.
Umeclidinium/vilanterol (Anoro/Ellipta) is now available to prescribe by healthcare professionals in primary care as well as secondary care in England, following a phased roll out.
The treatment, manufactured by GlaxoSmithKline and Theravance, is indicated in the UK as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.
It is a combination of two bronchodilators in a single dry powder inhaler, containing the long-acting muscarinic antagonist umeclidinium and the long-acting beta2 agonist vilanterol.
In a clinical study 98% of COPD patients were able to use the device correctly the first time following instruction and 98-99% of patients could still use it correctly six weeks later, according to the manufacturers.
The approved dose is 55/22mcg. It was granted marketing authorisation by the European Commission in May 2014.
Since July 2014 there has been a phased introduction, with availability initially limited to secondary care healthcare professionals to allow for local formulary applications.